Patrick Soon-Shiong

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
El Segundo, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Patrick Soon-Shiong, /s/ Charles Kenworthy, Manager of MP 13 Ventures, on behalf of itself and as General Partner of Cambridge Equities, and /s/ Charles Kenworthy, Manager of California Capital Equity and Manager...
Open signature details
/s/ Patrick Soon-Shiong, /s/ Charles Kenworthy, Manager of MP 13 Ventures, on behalf of itself and as General Partner of Cambridge Equities, and /s/ Charles Kenworthy, Manager of California Capital Equity and Manager of Nant Capital
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Patrick Soon-Shiong

Form 4 holding Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner

ImmunityBio, Inc.

Security class
Common Stock
Shares / value
251,018,873
Estimated value
$497,017,368
Report date
31 Mar 2026
Price
$1.98
Ownership
Indirect
Form 4 holding Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner

ImmunityBio, Inc.

Security class
Common Stock
Shares / value
29,757,911
Estimated value
$58,920,663
Report date
31 Mar 2026
Price
$1.98
Ownership
Direct
Form 4 holding Chief Executive Officer, Director, 10%+ Owner

NantHealth, Inc.

Security class
Common Stock
Shares / value
15,921,888
Estimated value
$31,219,638
Report date
28 Aug 2023
Price
$1.96
Ownership
Indirect
Form 4 holding Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner

ImmunityBio, Inc.

Security class
Common Stock
Shares / value
7,976,159
Estimated value
$15,792,794
Report date
31 Mar 2026
Price
$1.98
Ownership
See footnte
Form 4 holding Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner

ImmunityBio, Inc.

Security class
Restricted Stock Units
Shares / value
114,329
Estimated value
$782,010
Report date
22 Feb 2026
Price
$3.42
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner

ImmunityBio, Inc.

Security class
Second Amended and Restated Convertible Promissory Note
Shares / value
$480,000,000
Estimated value
Report date
31 Mar 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Patrick Soon-Shiong

4 IBRX

ImmunityBio, Inc.

Report period
31 Mar 2026
Transactions
2
Transaction value
$0
Accepted by SEC
02 Apr 2026, 20:08
Role
Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
Next action
Open filing details
4 IBRX

ImmunityBio, Inc.

Report period
22 Feb 2026
Transactions
3
Transaction value
-$506,079
Accepted by SEC
24 Feb 2026, 20:05
Role
Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
Next action
Open filing details
4 IBRX

ImmunityBio, Inc.

Report period
10 Feb 2026
Transactions
3
Transaction value
-$821,621
Accepted by SEC
12 Feb 2026, 21:29
Role
Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
Next action
Open filing details
4 IBRX

ImmunityBio, Inc.

Report period
22 Feb 2025
Transactions
3
Transaction value
-$143,883
Accepted by SEC
25 Feb 2025, 21:11
Role
Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
Next action
Open filing details
4 IBRX

ImmunityBio, Inc.

Report period
10 Feb 2025
Transactions
2
Transaction value
$0
Accepted by SEC
12 Feb 2025, 20:17
Role
Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
Next action
Open filing details
4 IBRX

ImmunityBio, Inc.

Report period
10 Dec 2024
Transactions
6
Transaction value
+$126,402,412
Accepted by SEC
12 Dec 2024, 21:20
Role
Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
Next action
Open filing details
4 IBRX

ImmunityBio, Inc.

Report period
22 Feb 2024
Transactions
2
Transaction value
$0
Accepted by SEC
26 Feb 2024, 16:36
Role
Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
Next action
Open filing details
4 IBRX

ImmunityBio, Inc.

Report period
29 Dec 2023
Transactions
2
Transaction value
+$410,000,000
Accepted by SEC
03 Jan 2024, 21:53
Role
Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
Next action
Open filing details
4 IBRX

ImmunityBio, Inc.

Report period
11 Sep 2023
Transactions
9
Transaction value
+$199,999,997
Accepted by SEC
13 Sep 2023, 21:07
Role
Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
Next action
Open filing details
4 IBRX

ImmunityBio, Inc.

Report period
12 May 2023
Transactions
1
Transaction value
+$30,455,859
Accepted by SEC
16 May 2023, 20:30
Role
Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
Next action
Open filing details
4 IBRX

ImmunityBio, Inc.

Report period
12 Dec 2022
Transactions
2
Transaction value
-$5.11
Accepted by SEC
14 Dec 2022, 15:23
Role
Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
Next action
Open filing details
4 IBRX

ImmunityBio, Inc.

Report period
31 Aug 2022
Transactions
6
Transaction value
+$315,096,248
Accepted by SEC
08 Nov 2022, 15:01
Role
Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
Next action
Open filing details
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .